Results 41 to 50 of about 5,580 (266)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi   +9 more
doaj   +1 more source

Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II

, 2018
Selective carbonic anhydrase (CA) inhibitors have gained a lot of importance owing to the implication of specific isoforms of CA in certain diseases like glaucoma, leukemia, cystic fibrosis, and epilepsy.
Danish Idrees, Shahzaib Ahamad, Datta, Bhaskar, Hadianawala, Murtuza, Imtaiyaz Hassan, Md, Amarjyoti Das Mahapatra, Sonam Roy, Ahamad, Shahzaib, Khan, Parvez, Idrees, Danish, Mahapatra, Amarjyoti Das, Bhaskar Datta, Parvez Khan, Md. Imtaiyaz Hassan, Roy, Sonam, Murtuza Hadianawala   +15 more
core   +1 more source

Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists

, 2022
New quinazoline-sulfonylurea hybrids were prepared and examined for their in vivo anti-hyperglycemic activities in STZ-induced hyperglycemic rats using glibenclamide as a reference drug.
Mohamed F. Zayed, Alshaeri, Heba K., Bamanie, Faida H., Moudi M. Alasmari, Mohamed Ayman El-Zahabi, Faida H. Bamanie, Mohamed Moustafa, Zohair Al-Marzooki, El-Zahabi, Mohamed Ayman, Zayed, Mohamed F., Moustafa, Mohamed, Al-Marzooki, Zohair, Salah Ghareeb, Alasmari, Moudi M., Heba K. Alshaeri, Ghareeb, Salah   +15 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors

European Journal of Medicinal Chemistry Reports, 2023
Overactivated NLRP3 inflammasome has been shown to associate with an increasing number of disease conditions. Activation of the NLRP3 inflammasome results in caspase-1-catalyzed formation of active pro-inflammatory cytokines (IL-1β and IL-18) resulting ...
Pritam Thapa, Sunil P. Upadhyay, Vikas Singh, Varun C. Boinpelly, Jianping Zhou, David K. Johnson, Prajwal Gurung, Eung Seok Lee, Ram Sharma, Mukut Sharma   +9 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor II [PDF]

, 1994
Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to β-cell membranes with 8–9-fold higher koff rate and 2.5–3-fold higher kon rate compared to glibenclamide (see ...
Kramer, Werner, Kowalewski, Simone, Hartz, Detlev, Gutjahr, Ulrike, Summ, Hans-Dieter, Müller, Günter, Girbig, Frank   +6 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

In Silico Study of New Sulfonylurea Analogs as Potential Antidiabetic Agents: ADMET, Molecular Docking and Dynamics, MM-GBSA and DFT Approach

Journal of Chemistry
Type 2 diabetes mellitus (T2DM) remains one of the leading causes of death globally. Current treatments of this disease involve using sulfonylurea, which is associated with cardiovascular risk and insulin resistance, among others.
Vhushavhelo Musinyali, Kabelo P. Mokgopa, Simon S. Mnyakeni-Moleele, Tendamudzimu Tshiwawa, Ndivhuwo R. Tshiluka   +4 more
doaj   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source